Erasca, Inc. (ERAS)
ERAS price $14.49 -0.12 -0.85%
- Ticker
- ERAS
- Price
- $14.49
- Change
- -0.12 -0.85%
- Market cap
- $5.07B
- P/E
- -15.39
- Sector
- Healthcare
- Industry
- Biotechnology
- Stocklytics score
- 67
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid…